FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles
Franz Ricklefs, Cécile L. Maire, Jakob Matschke, Lasse Dührsen, Thomas Sauvigny, Mareike Holz, Katharina Kolbe, Sven Peine, Christel Herold‐Mende, Bob S. Carter, E. Antonio Chiocca, Sean Lawler, Manfred Westphal, Katrin Lamszus
Abstract
Extracellular vesicles (EVs) are known for their important role in cancer progression and hold considerable potential as a source for tumor biomarkers. However, purification of tumor-specific EVs from patient plasma is still an urgent unmet need due to contamination by normal host cell-derived EVs, that results in compromised analytical sensitivity. Here we identified fatty acid synthase (FASN), a key lipogenic enzyme which is highly expressed in malignant glioma cells, to be elevated in CD63- and CD81-positive EVs in glioma patient plasma samples, opening vital opportunities to sort brain tumor-specific EVs.